On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Coterra Energy CTRA. “It can make money even at these levels,” he noted.
On Oct. 10, Scotiabank analyst Paul Cheng maintained Coterra Energy with a Sector Outperform and lowered the price target from $35 to $32.
“It trades with the whole group, and the group is actually trading very, very well,” Cramer said when asked about Energy Transfer ET. “You're in good shape with ET.”
Energy Transfer will release earnings for the third quarter on Wednesday, Nov. 6, after the closing bell.
“Tim Wentworth [CEO of Walgreens] is really an excellent CEO. The bad news is you're up against Amazon AMZN,” Cramer said when asked about Walgreens Boots Alliance, Inc. WBA. “I'm a a believer in Tim, I really hope it works. But that is a one tough spot he's got himself in.”
On Oct. 15, Walgreens reported fourth-quarter fiscal year 2024 sales of $37.55 billion, up 6% year over year (+6.1% on constant currency), beating the consensus of $35.76 billion, reflecting sales growth across all segments.
The “Mad Money” host said it's going to be a good quarter for Dover DOV. “It's in the data center, that's why we like it,” he added.
On Oct. 17, Mizuho analyst Brett Linzey maintained Dover with an Outperform and raised the price target from $200 to $220.
“This is a very tough situation because all of cosmetics are in a downturn that is so staggering that it caught everybody by surprise,” Cramer said when asked about e.l.f. Beauty, Inc. ELF.
“I do think that, when they come back, this one will come back faster than all of them,” he added.
On Oct. 16, Truist Securities analyst Bill Chappell maintained e.l.f. Beauty with a Buy and lowered the price target from $210 to $130.
Price Action:
- Energy Transfer shares fell 0.5% to settle at $16.41 on Friday.
- Walgreens shares gained 1.2% to close at $10.79.
- Coterra Energy shares fell 1.2% to close at $23.78 on Friday.
- e.l.f. Beauty shares gained 0.2% to settle at $108.20.
- Dover shares fell 0.3% to close at $194.38 on Friday.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.